Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: A randomized, active-controlled, double-blind study

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 12, 2002, Pages 2043-2052

  Kovacs, Thomas O G ^a   Wilcox, C Mel ^b   Devault, Kenneth ^c   Miska, David ^d,e   Bochenek, Wieslaw ^d,e   Avner, Dennis ^f   Berry, William ^f   Blitstein, Mark ^f   Campbell, Donald ^f   Cooper, James N ^f   Giannella, Ralph A ^f   Gitlin, Norman ^f   Hee, Vernon ^f   Johnson, David A ^f   Kornfield, Robert ^f   Meier, Peter ^f   Miner, Philip ^f   Movva, Rao ^f   Orchard, John ^f   Person, John ^f   Pruitt, Ron ^f   Rift, Dennis ^f   Rodgers, John ^f   Safdi, Alan ^f   Smith, William B ^f   Snape, William ^f   Weisman, Stuart ^f   Beg, Mirza ^e   Dasen, Sue ^f   Nothington, Robert ^e   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAYO CLINIC   (United States)

^d WYETH AYERST RESEARCH   (United States)

^e WYETH AYERST RESEARCH   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL CRAMP; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FEMALE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; NIZATIDINE; OMEPRAZOLE; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; SULFOXIDES; TREATMENT OUTCOME;

EID: 0036918696     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01366.x     Document Type: Article

References (30)

1. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991; 26: 73-81.
2. Petersen H. The prevalence of gastroesophageal reflux disease. Scand J Gastroenterol 1995; 30(Suppl. 211): 5-6.
3. Altorki NK, Skinner DB. Pathophysiology of gastroesophageal reflux. Am J Med 1989; 86: 685-9.
4. Ogorek CP, Cohen S. Gastroesophageal reflux disease: New concepts in pathophysiology. Gastroenterol Clin North Am 1989; 18: 275-92.
5. Dubois A. Clinical relevance of gastroduodenal dysfunction in reflux esophagitis. J Clin Gastroenterol 1986; 8: 17-25.
6. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
7. Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial Pantoprazole US GERD Study Group. Am J Gastroenterol 2000; 95: 3071-80.
8. Dammann HG. Pantoprazole: A pharmacological and clinical profile. Today's Therapeutic Trends 1997; 15: 109-36.
9. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: An updated review. Int J Clin Pharmacol Ther 1996; 34: S31-50.
10. Shin JM, Besancon M, Prinz C, Simon A, Sachs G. Continuing development of acid pump inhibitors: Site of action of pantoprazole. Aliment Pharmacol Ther 1994; 8: 11-23.
11. Koop H, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study. J Clin Gastroenterol 1995; 20: 192-5.
12. Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8: 47-52.
13. Dammann HG, Kleist DH. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastroesophageal reflux disease: Multicenter, open randomized, controlled studies. In: Domschje W, ed. International Clinical Practice Series. Kent: Wels Medical Ltd, 1997; 23-9.
14. Mossner J, Holscher AH; Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
15. Corinaldesi R, Valentini M, Belaiche J, et al. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71.
16. Vicari F, Belin J, Marek L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: Results of a French multicentric double-blind comparative trial Gastroenterol 1998; 114: A324(Abstract).
17. Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K8-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol 1999; 14: 251-7.
18. Dupas JL, Houcke P, Samoyeau R. French Collaborative Pantaprazole Study G. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol 2001; 25: 245-50.
19. van Rensburg CJ, Honiball PJ. Grundling HD, et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 397-401.
20. Dettmer A, Vogt R, Sielaff F, et al. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998; 12: 86572.
21. van Zyl JH, de K Grundling H, van Rensburg CJ, et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: A randomized, double-blind, parallel, and multicentre study. Eur J Gastro-enterol Hepatol 2000; 12: 197-202.
22. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastro-enterology 1988; 95: 903-12.
23. SAS Institute I. SAS/STAT® User's Guide, Version 6, 4th edn. Cary, NC: SAS Institute, Inc. 1987.
24. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997: 112: 1798-810.
25. Lachman L, Howden CW, Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000: 95: 57-61.
26. Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155: 1465-71.
27. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
28. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
29. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-42.
30. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts JL. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33: 523-9.